The paradox of immunotherapy in NASH-HCC

被引：0
作者：
Yao Peng
Chi Chun Wong
Jun Yu
机构：
[1] South China University of Technology,Department of Gastroenterology, Guangzhou First People’s Hospital
[2] The Chinese University of Hong Kong,Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK
来源：
Signal Transduction and Targeted Therapy | / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 5 条
  • [1] Pinter M(2021)The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review JAMA Oncol. 7 113-123
  • [2] Jain RK(2018)The immunology of hepatocellular carcinoma Nat. Immunol. 19 222-232
  • [3] Duda DG(2021)IMbrave150: updated overall survival data from a global, randomized, open-label phase III study of atezolizumab+ bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma J. Clin. Oncol. 39 abstr 267-undefined
  • [4] Ringelhan M(undefined)undefined undefined undefined undefined-undefined
  • [5] Finn RS(undefined)undefined undefined undefined undefined-undefined
1